Clinical Trial Update: LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing ceritinib (LDK378) to chemotherapy in previously untreated ALK-rearranged non-small cell lung cancer; results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Chemotherapy (platinum-based) (platinum-based chemotherapy)
• Zykadia (ceritinib) (ceritinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Non-Small Cell Lung Cancer | Phase 3 | Status: COMPLETED | Results posted: 2017-09-21